Loading...
Market
What will be the key focus areas announced by Jay Bhattacharya within 3 months if appointed as NIH Director?
2
Jay Bhattacharya•National Institutes of Health•NIH•Washington Post•Bhattacharya•Francis Collins•Fauci
Resolution / Starting Odds
COVID-19 policies • 25%
Healthcare innovation • 25%
Transparency and accountability • 25%
Other • 25%
Official NIH press releases or credible news reports
Story
COVID-19 Critic Jay Bhattacharya Emerges as Top Candidate for NIH Director
Nov 16, 2024, 07:24 PM
Jay Bhattacharya, a prominent critic of the National Institutes of Health (NIH), has emerged as a leading candidate to head the agency, according to a report by the Washington Post. Bhattacharya, who has been vocal about his views on COVID-19 policies, has garnered support from various quarters for his evidence-based criticism and intellectual rigor. His potential appointment has been met with enthusiasm by those who know him personally, citing his kindness, humility, and vision. Supporters believe Bhattacharya could transform the NIH and restore its credibility, which they feel has been compromised during the COVID-19 pandemic. Critics, including Francis Collins and Fauci, have previously labeled him a 'fringe epidemiologist,' but supporters argue he will uncover hidden secrets within the NIH.
View original story
Similar markets
Focus on pandemic preparedness • 25%
Reform in pharmaceutical company collaborations • 25%
Emphasis on non-pharmaceutical research • 25%
Other policy initiative • 25%
COVID-19 Response • 25%
Chronic Disease • 25%
Mental Health • 25%
Other • 25%
Academic freedom • 25%
Research funding allocation • 25%
Public health initiatives • 25%
Other focus area • 25%
COVID-19 research • 25%
Chronic diseases • 25%
Mental health • 25%
Other emerging health issues • 25%
Pandemic Preparedness • 25%
Chronic Disease Research • 25%
Mental Health Initiatives • 25%
Other • 25%
COVID-19 management • 25%
Cancer research • 25%
Mental health • 25%
Other • 25%
Confirmed • 33%
Rejected • 33%
Withdrawn • 34%
Mostly Positive • 25%
Mixed • 25%
Mostly Negative • 25%
Indifferent • 25%
Yes • 50%
No • 50%
Mostly positive • 25%
Mostly negative • 25%
Mixed opinions • 25%
Indifferent • 25%
Increase in NIH funding for non-pharmaceutical research • 25%
Reduction in NIH collaborations with pharmaceutical companies • 25%
No significant changes in NIH leadership or policy • 25%
Other significant leadership changes • 25%